Developer docs
API playgroundTry for free, no card

Search company profiles

Coya Therapeutics

Full company profile

uuid00005h5

Namestring
Coya Therapeutics
Legal namestring
Coya Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2020
Descriptiontext

Coya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell (Treg)-based therapeutics for neurodegenerative, autoimmune, and metabolic diseases. Founded around 2020-2021 and headquartered in Houston, Texas, the company is publicly traded on NASDAQ under ticker COYA and was established to commercialize the Treg technology platform licensed from Dr. Stanley Appel at Houston Methodist Hospital. Its pipeline addresses diseases with no approved disease-modifying therapies, with primary focus on amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer's disease. The senior leadership team brings over 20 years of pharmaceutical experience, and the Scientific Advisory Board is anchored by Shimon Sakaguchi (discoverer of Tregs) and Dr. Stanley Appel (pioneer of Treg therapy in ALS).

Short descriptiontext

Coya Therapeutics is a clinical-stage biotechnology company developing multi-modality regulatory T cell (Treg) therapies — biologics, exosomes, and cell therapy — for neurodegenerative, autoimmune, and metabolic diseases, with lead asset COYA 302 in Phase 2 ALS trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Treg therapeutics, regulatory T cells, neurodegenerative disease therapy, biologics development, autoimmune disease therapy
Industry2 codes
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Collaboration / Licensing Revenue
TypeLicensing Royalties
Description

Pre-commercial clinical-stage biotech generating collaboration revenue from strategic partners (e.g., milestone-based payments from Dr. Reddy's Laboratories tied to ALSTARS patient dosing). FY2025 collaboration revenues of $7.9 million versus $3.6 million in FY2024. No approved products; future revenue expected from out-licensing, milestone payments, and eventual product commercialization.

biospace.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1COYA 302
Description

Investigational Treg-enhancing biologic combination therapy (low-dose IL-2 + CTLA-4 Ig) for ALS, FTD, and other neurodegenerative diseases; lead asset in Phase 2 ALSTARS trial.

coyatherapeutics.com
+5 more records
Core offering1 text field

Coya Therapeutics is a clinical-stage biotechnology company developing a multi-modality regulatory T cell (Treg) therapeutic platform intended to restore Treg function and suppress chronic neuroinflammation. Its pipeline spans investigational Treg-enhancing biologics (lead asset COYA 302, a low-dose IL-2 + CTLA-4 Ig combination in Phase 2 for ALS), Treg-derived exosomes, and autologous Treg cell therapy, targeting neurodegenerative, autoimmune, and metabolic diseases with no approved disease-modifying therapies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Phase 1 ALS trial (COYA 101) showed halting of fast decline typically seen in ALS patients following expanded autologous Treg infusions
+4 more records
Product overview1 text field

Coya Therapeutics is a clinical-stage biotechnology company developing a multi-modality Treg (regulatory T cell) therapy platform addressing neurodegenerative, autoimmune, and metabolic diseases. The portfolio is organized into three therapeutic modalities: (1) Treg-modifying biologics, led by COYA 302 (a low-dose IL-2 + CTLA-4 Ig combination currently in the Phase 2 ALSTARS trial for ALS and an FDA IND-accepted Phase 2 trial for FTD, with FDA Fast Track Designation in ALS), COYA 301 (a proprietary low-dose IL-2 in a pre-filled syringe for subcutaneous injection), and COYA 303 (an LD IL-2/GLP-1 RA combination candidate for Alzheimer's); (2) allogeneic Treg-derived exosomes, including COYA 201 (Treg-derived exosomes) and COYA 206 (tethered exosome polymer hybrids for targeted drug/cargo delivery); and (3) autologous Treg cell therapy, anchored by COYA 101 (expanded autologous Tregs for ALS, with Coya actively seeking strategic options for the asset). The platform is supported by Coya's proprietary CTreg (Cryopreservation for Tregs) manufacturing technology and TAI (Tregs Against Inflammation) and iscEXO (immunosuppressive cell Exosome) platforms.

Product and service6 records
1COYA 302
CategoryTreg-Enhancing Biologic Combination Therapy
Description

Investigational combination biologic therapy pairing low-dose IL-2 with CTLA-4 Ig that synergistically enhances Treg function and depletes effector T cells and macrophages to reduce inflammation. Coya's lead asset, in the Phase 2 ALSTARS trial for ALS (NCT07161999) and an FDA IND-accepted Phase 2 trial for FTD; granted FDA Fast Track Designation in ALS.

2COYA 301
CategoryTreg-Enhancing Biologic Therapy
Description

Proprietary low-dose IL-2 Treg-enhancing biologic therapy supplied in a pre-filled syringe for subcutaneous injection; plays a key role in the development, expansion, activity, and survival of Tregs. Investigational product candidate not yet approved by the FDA.

3COYA 303
CategoryCombination Biologic Candidate (LD IL-2 / GLP-1 RA)
Description

Investigational combination biologic candidate pairing low-dose IL-2 with a GLP-1 receptor agonist; demonstrated potent systemic and brain anti-inflammatory efficacy in vivo in an animal study, supporting potential development for Alzheimer's and other neurodegenerative diseases.

4COYA 201
CategoryAllogeneic Treg-Derived Exosome Therapy
Description

First-in-class allogeneic exosomes derived from Tregs that suppress inflammation and provide anti-inflammatory and neuroprotective effects. Investigational product candidate not yet approved by the FDA.

5COYA 206
CategoryTethered Exosome Platform (Exosome Polymer Hybrids)
Description

Proprietary exosome polymer hybrid platform licensed by Coya with exclusive worldwide rights for research, development, and manufacturing, enabling exosomes to target proteins of interest while delivering drugs and/or cargo. Investigational product candidate not yet approved by the FDA.

6COYA 101
CategoryAutologous Treg Cell Therapy
Description

Autologous Treg cell therapy for ALS in which patient-derived dysfunctional Tregs are removed via leukapheresis, expanded ex vivo, cryopreserved, and re-infused using Coya's patent-pending CTreg™ cryopreservation technology that enables serial infusions from a single manufacturing round. Investigational product candidate; Coya is actively seeking strategic options for this asset.

Scale indicator20 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Research collaboration and clinical translation partner. Dr. Stanley Appel and his team at Houston Methodist conducted the first-in-human Phase 1 trial of expanded autologous Tregs in ALS and continue to collaborate on Treg-based therapy development; published Treg dysfunction biomarker study in FTD in Brain Communications. Source of the licensed Treg technology underlying Coya's pipeline.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

$4.2 million milestone payment from Dr. Reddy's triggered by dosing of first ALS patients in the ALSTARS Phase 2 trial of COYA 302 (December 2025); strategic collaboration on technology transfer and commercial readiness for low-dose IL-2 manufacturing.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing autologous cell therapies for neurodegenerative diseases, most notably NurOwn for ALS; directly comparable as a small-cap cell/immunology therapy developer targeting the same ALS indication as Coya's COYA 302.

TypeDirect peer
Description

Clinical-stage cell therapy company developing allogeneic and transplant-compatible cell therapies for neurological and ophthalmic conditions; comparable modality (cell-based therapeutics for neurodegeneration) and similar clinical-stage profile.

TypeDirect peer
Description

Cell therapy company developing mesenchymal stem cell-based treatments for inflammatory and immune-mediated diseases; Coya's incoming CMO Fred Grossman was previously CMO at Mesoblast, and the companies share a cell-based approach to inflammatory disease.

TypeDirect peer
Description

Clinical-stage neurology company developing novel therapies for neurodegenerative conditions including ALS-related symptoms; comparable as a small-cap clinical-stage neuroscience company.

TypeDirect peer
Description

Clinical-stage biotechnology company developing RNA-based therapeutics for rare and neurodegenerative genetic diseases; comparable as a small-cap clinical-stage biotech focused on neurological indications.

TypeDirect peer
Description

Clinical-stage immunology biotech developing therapies that modulate immune responses in inflammatory and autoimmune diseases; comparable Treg/immunology focus for autoimmune indications in Coya's pipeline.

TypeBroad incumbent
Description

Large biotech with an established ALS franchise (Tofersen/SOD1-ALS through partnership with Ionis) and broader neuroscience pipeline; comparable as a major incumbent in neurodegenerative disease therapeutics with overlapping ALS focus.

TypeBroad incumbent
Description

Established RNA-targeted therapeutics company with a substantial neurology pipeline including partnered ALS programs; comparable as a broader player in neurodegenerative drug development.

TypeBroad incumbent
Description

Commercial-stage RNAi therapeutics company with programs in rare neurological and metabolic diseases; comparable as a broader biotech pursuing innovative modalities for serious diseases including neurodegeneration.

TypeOthers
Description

Strategic manufacturing collaborator and equity investor in Coya ($10M private placement, $4.2M milestone); provides technology transfer and scale-up manufacturing for low-dose IL-2 in support of COYA 302 commercial readiness.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Coya Therapeutics

Biopharmaceuticalscoyatherapeutics.com

Coya Therapeutics is a clinical-stage biotechnology company developing multi-modality regulatory T cell (Treg) therapies — biologics, exosomes, and cell therapy — for neurodegenerative, autoimmune, and metabolic diseases, with lead asset COYA 302 in Phase 2 ALS trials.

What Coya Therapeutics does

Coya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell (Treg)-based therapeutics for neurodegenerative, autoimmune, and metabolic diseases. Founded around 2020-2021 and headquartered in Houston, Texas, the company is publicly traded on NASDAQ under ticker COYA and was established to commercialize the Treg technology platform licensed from Dr. Stanley Appel at Houston Methodist Hospital. Its pipeline addresses diseases with no approved disease-modifying therapies, with primary focus on amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer's disease. The senior leadership team brings over 20 years of pharmaceutical experience, and the Scientific Advisory Board is anchored by Shimon Sakaguchi (discoverer of Tregs) and Dr. Stanley Appel (pioneer of Treg therapy in ALS).

Coya Therapeutics firmographics

Firmographics
Name
Coya Therapeutics
Legal name
Coya Therapeutics, Inc.
Website
https://coyatherapeutics.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Coya Therapeutics is a clinical-stage biotechnology company developing multi-modality regulatory T cell (Treg) therapies — biologics, exosomes, and cell therapy — for neurodegenerative, autoimmune, and metabolic diseases, with lead asset COYA 302 in Phase 2 ALS trials.
Ownership category
akta.pro rank

Coya Therapeutics industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Treg therapeutics
  • Regulatory T cells
  • Neurodegenerative disease therapy
  • Biologics development
  • Autoimmune disease therapy

Where Coya Therapeutics is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Coya Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Collaboration / Licensing Revenue: Pre-commercial clinical-stage biotech generating collaboration revenue from strategic partners (e.g., milestone-based payments from Dr. Reddy's Laboratories tied to ALSTARS patient dosing). FY2025 collaboration revenues of $7.9 million versus $3.6 million in FY2024. No approved products; future revenue expected from out-licensing, milestone payments, and eventual product commercialization.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels9 records

Coya Therapeutics product offering

Product offering

Core offering

Coya Therapeutics is a clinical-stage biotechnology company developing a multi-modality regulatory T cell (Treg) therapeutic platform intended to restore Treg function and suppress chronic neuroinflammation. Its pipeline spans investigational Treg-enhancing biologics (lead asset COYA 302, a low-dose IL-2 + CTLA-4 Ig combination in Phase 2 for ALS), Treg-derived exosomes, and autologous Treg cell therapy, targeting neurodegenerative, autoimmune, and metabolic diseases with no approved disease-modifying therapies.

Product overview

Coya Therapeutics is a clinical-stage biotechnology company developing a multi-modality Treg (regulatory T cell) therapy platform addressing neurodegenerative, autoimmune, and metabolic diseases. The portfolio is organized into three therapeutic modalities: (1) Treg-modifying biologics, led by COYA 302 (a low-dose IL-2 + CTLA-4 Ig combination currently in the Phase 2 ALSTARS trial for ALS and an FDA IND-accepted Phase 2 trial for FTD, with FDA Fast Track Designation in ALS), COYA 301 (a proprietary low-dose IL-2 in a pre-filled syringe for subcutaneous injection), and COYA 303 (an LD IL-2/GLP-1 RA combination candidate for Alzheimer's); (2) allogeneic Treg-derived exosomes, including COYA 201 (Treg-derived exosomes) and COYA 206 (tethered exosome polymer hybrids for targeted drug/cargo delivery); and (3) autologous Treg cell therapy, anchored by COYA 101 (expanded autologous Tregs for ALS, with Coya actively seeking strategic options for the asset). The platform is supported by Coya's proprietary CTreg (Cryopreservation for Tregs) manufacturing technology and TAI (Tregs Against Inflammation) and iscEXO (immunosuppressive cell Exosome) platforms.

Differentiator

Problem solved

Functional benefit

Brands

  • COYA 302: Investigational Treg-enhancing biologic combination therapy (low-dose IL-2 + CTLA-4 Ig) for ALS, FTD, and other neurodegenerative diseases; lead asset in Phase 2 ALSTARS trial.
  • COYA 301
  • COYA 201
  • COYA 206
  • COYA 101
  • COYA 303

Products and services

  • COYA 302 Investigational combination biologic therapy pairing low-dose IL-2 with CTLA-4 Ig that synergistically enhances Treg function and depletes effector T cells and macrophages to reduce inflammation. Coya's lead asset, in the Phase 2 ALSTARS trial for ALS (NCT07161999) and an FDA IND-accepted Phase 2 trial for FTD; granted FDA Fast Track Designation in ALS.
  • COYA 301 Proprietary low-dose IL-2 Treg-enhancing biologic therapy supplied in a pre-filled syringe for subcutaneous injection; plays a key role in the development, expansion, activity, and survival of Tregs. Investigational product candidate not yet approved by the FDA.
  • COYA 303 Investigational combination biologic candidate pairing low-dose IL-2 with a GLP-1 receptor agonist; demonstrated potent systemic and brain anti-inflammatory efficacy in vivo in an animal study, supporting potential development for Alzheimer's and other neurodegenerative diseases.
  • COYA 201 First-in-class allogeneic exosomes derived from Tregs that suppress inflammation and provide anti-inflammatory and neuroprotective effects. Investigational product candidate not yet approved by the FDA.
  • COYA 206 Proprietary exosome polymer hybrid platform licensed by Coya with exclusive worldwide rights for research, development, and manufacturing, enabling exosomes to target proteins of interest while delivering drugs and/or cargo. Investigational product candidate not yet approved by the FDA.
  • COYA 101 Autologous Treg cell therapy for ALS in which patient-derived dysfunctional Tregs are removed via leukapheresis, expanded ex vivo, cryopreserved, and re-infused using Coya's patent-pending CTreg™ cryopreservation technology that enables serial infusions from a single manufacturing round. Investigational product candidate; Coya is actively seeking strategic options for this asset.

Quantifiable outcome

  • Phase 1 ALS trial (COYA 101) showed halting of fast decline typically seen in ALS patients following expanded autologous Treg infusions
  • +4 more outcomes

Companies that use Coya Therapeutics

Customer profile

Segments5 records

Ideal customer profiles3 records

Coya Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Coya Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship.

  • Houston Methodist Neurological InstituteflagshipStrategic or Co-development PartnerResearch collaboration and clinical translation partner. Dr. Stanley Appel and his team at Houston Methodist conducted the first-in-human Phase 1 trial of expanded autologous Tregs in ALS and continue to collaborate on Treg-based therapy development; published Treg dysfunction biomarker study in FTD in Brain Communications. Source of the licensed Treg technology underlying Coya's pipeline.
  • Dr. Reddy's Laboratories (development milestone partner)flagshipStrategic or Co-development Partner$4.2 million milestone payment from Dr. Reddy's triggered by dosing of first ALS patients in the ALSTARS Phase 2 trial of COYA 302 (December 2025); strategic collaboration on technology transfer and commercial readiness for low-dose IL-2 manufacturing.

Scale indicators20 records

Recent moves6 records

Expansion highlights6 records

Coya Therapeutics competitors and assessment

Company assessment

Direct peers

  • BrainStorm Cell Therapeutics: Clinical-stage biotech developing autologous cell therapies for neurodegenerative diseases, most notably NurOwn for ALS; directly comparable as a small-cap cell/immunology therapy developer targeting the same ALS indication as Coya's COYA 302.
  • Lineage Cell Therapeutics: Clinical-stage cell therapy company developing allogeneic and transplant-compatible cell therapies for neurological and ophthalmic conditions; comparable modality (cell-based therapeutics for neurodegeneration) and similar clinical-stage profile.
  • Mesoblast: Cell therapy company developing mesenchymal stem cell-based treatments for inflammatory and immune-mediated diseases; Coya's incoming CMO Fred Grossman was previously CMO at Mesoblast, and the companies share a cell-based approach to inflammatory disease.
  • Helius Medical Technologies: Clinical-stage neurology company developing novel therapies for neurodegenerative conditions including ALS-related symptoms; comparable as a small-cap clinical-stage neuroscience company.
  • ProQR Therapeutics: Clinical-stage biotechnology company developing RNA-based therapeutics for rare and neurodegenerative genetic diseases; comparable as a small-cap clinical-stage biotech focused on neurological indications.
  • Equillium: Clinical-stage immunology biotech developing therapies that modulate immune responses in inflammatory and autoimmune diseases; comparable Treg/immunology focus for autoimmune indications in Coya's pipeline.

Broad incumbents

  • Biogen: Large biotech with an established ALS franchise (Tofersen/SOD1-ALS through partnership with Ionis) and broader neuroscience pipeline; comparable as a major incumbent in neurodegenerative disease therapeutics with overlapping ALS focus.
  • Ionis Pharmaceuticals: Established RNA-targeted therapeutics company with a substantial neurology pipeline including partnered ALS programs; comparable as a broader player in neurodegenerative drug development.
  • Alnylam Pharmaceuticals: Commercial-stage RNAi therapeutics company with programs in rare neurological and metabolic diseases; comparable as a broader biotech pursuing innovative modalities for serious diseases including neurodegeneration.

Others

  • Dr. Reddy's Laboratories: Strategic manufacturing collaborator and equity investor in Coya ($10M private placement, $4.2M milestone); provides technology transfer and scale-up manufacturing for low-dose IL-2 in support of COYA 302 commercial readiness.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Coya Therapeutics social profiles

Digital presence

Coya Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Coya Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

Coya Therapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Coya Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coya Therapeutics

What does Coya Therapeutics do?

Coya Therapeutics is a clinical-stage biotechnology company developing a multi-modality regulatory T cell (Treg) therapeutic platform intended to restore Treg function and suppress chronic neuroinflammation. Its pipeline spans investigational Treg-enhancing biologics (lead asset COYA 302, a low-dose IL-2 + CTLA-4 Ig combination in Phase 2 for ALS), Treg-derived exosomes, and autologous Treg cell therapy, targeting neurodegenerative, autoimmune, and metabolic diseases with no approved disease-modifying therapies.

Is Coya Therapeutics a public or private company?

Coya Therapeutics is a public company. It is classified as public and is currently operating.

When was Coya Therapeutics founded?

Coya Therapeutics was founded in 2020. It employs 11 to 50 people.

Where is Coya Therapeutics based?

Coya Therapeutics is headquartered in Houston, United States, in the North America region.

How does Coya Therapeutics make money?

One revenue line is on record: collaboration / Licensing Revenue.

Who are Coya Therapeutics's main competitors?

Direct peers on record are BrainStorm Cell Therapeutics, Lineage Cell Therapeutics, Mesoblast, Helius Medical Technologies, ProQR Therapeutics and Equillium. Broad incumbents are Biogen, Ionis Pharmaceuticals and Alnylam Pharmaceuticals. Dr. Reddy's Laboratories is listed as an others.

Does Coya Therapeutics have an API?

No public API is recorded for Coya Therapeutics.

What industry is Coya Therapeutics in?

Coya Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsCoya Therapeutics (NASDAQ:COYA) Cut to “Strong Sell” at Wall Street ZenWall Street Zen downgraded Coya Therapeutics to a strong sell rating. The stock has a consensus rating of Moderate Buy with a $15 price target, and the company reported a loss of $0.45 per share for the quarter.American Banking and Market NewsCoya Therapeutics (NASDAQ:COYA) Given Buy Rating at HC WainwrightHC Wainwright reissued a buy rating on Coya Therapeutics with a $18.00 price target. The stock opened at $3.27, and analysts have a consensus price target of $15.00. The company reported a loss of $0.45 per share for the quarter, missing estimates.Quiver QuantitativeCoya Reports $10.6 Million Third-Quarter Loss as ALSTARS Enrollment Completes | COYA Stock NewsCoya Therapeutics reported a Q3 2026 net loss of $10.6 million and $234,134 in collaboration revenue. The company completed enrollment in its Phase 2/3 ALSTARS trial of COYA 302 for ALS, enrolling 137 participants, and expects topline data in early Q2 2027.American Banking and Market NewsContrasting Coya Therapeutics (NASDAQ:COYA) and Agenus (NASDAQ:AGEN)Agenus and Coya Therapeutics are compared on valuation, risk, earnings, and analyst ratings. Agenus beats Coya on 10 of 14 factors, with higher revenue and earnings, but Coya has a stronger consensus rating and higher upside. Analysts favor Coya's lower volatility and higher probable upside.American Banking and Market NewsAnalyzing Coya Therapeutics (COYA) and Its RivalsCoya Therapeutics is compared to biotechnology competitors on profitability, risk, analyst ratings, and ownership. It has a consensus price target of $15.33, implying 324.75% upside, and 39.8% institutional ownership. The company develops Treg-based therapies, including COYA 101 for ALS.American Banking and Market NewsCoya Therapeutics, Inc. (NASDAQ:COYA) Stock Has Average Price Target of $15.33 According to BrokeragesCoya Therapeutics received an average analyst rating of Moderate Buy with a $15.33 price target. The company reported Q2 EPS of -$0.28, beating the -$0.35 estimate, and revenue of $0.24 million. Shares opened at $4.95, with a 52-week range of $3.71 to $7.75.MarketBeatCoya Therapeutics, Inc. (NASDAQ:COYA) Stock Has Average Price Target of $15.33 According to BrokeragesCoya Therapeutics received a Moderate Buy rating from seven analysts, with an average price target of $15.33. The company reported Q2 EPS of -$0.28, beating the -$0.35 consensus, and revenue of $0.24 million. Analysts expect -$1.34 EPS for the current year.Markets DailyMadrigal Pharmaceuticals (NASDAQ:MDGL) & Coya Therapeutics (NASDAQ:COYA) Critical ContrastCoya Therapeutics and Madrigal Pharmaceuticals are compared on valuation, risk, and analyst ratings. Coya has higher probable upside (207.28%) versus Madrigal (48.92%), with Madrigal trading at a lower P/E ratio. Analysts favor Coya due to its higher upside potential.Longevity.TechnologyCoya Therapeutics completes enrollment in ALSTARS ALS trialCoya Therapeutics completed enrollment of 120 participants in the Phase 2/3 ALSTARS trial for COYA 302 in ALS. The study randomizes 1:1:1 to two dosing regimens or placebo for 24 weeks, with topline data expected in early Q2 2027. Coya retains U.S. development and regulatory responsibility.American Banking and Market NewsCoya Therapeutics (NASDAQ:COYA) and C4 Therapeutics (NASDAQ:CCCC) Financial ReviewCoya Therapeutics and C4 Therapeutics are compared on financial metrics, with Coya showing lower revenue but higher earnings and a lower price-to-earnings ratio. Analysts rate Coya more favorably, citing a higher consensus price target and lower volatility. Coya's Treg-based pipeline includes a Phase 2a trial for ALS.